Robert Radie named president & CEO of TransMolecular
This article was originally published in Scrip
TransMolecular (US) has appointed Robert Radie president and chief executive officer. Michael Egan, the company's former president and CEO, has been promoted to vice-chairman. Mr Radie, who previously served as a full-time business development consultant for the company, has more than 23 years' experience in the pharmaceutical and biotechnology industry. Before joining TransMolecular, he was executive vice-president and chief business officer at Prestwick Pharmaceuticals, and vice-president of project management and chief business officer at Morphotek.